UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First report of real-world patient characteristics and treatment patterns from POLARIS: Palbociclib in hormone receptor-positive (HR+) advanced breast cancer: A prospective, multicenter, noninterventional study

Annals of oncology, 2018-10, Vol.29, p.viii112-viii113

2018

Volltextzugriff (PDF)

Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer

Cell death & disease, 2015-03, Vol.6 (3), p.e1699-e1699

2015

Volltextzugriff (PDF)

Phase 1b/2 safety and efficacy of TAK-228 (MLN0128), plus exemestane (E) or fulvestrant (F) in postmenopausal women with ER + /HER2- metastatic breast cancer (MBC)

Annals of oncology, 2016-10, Vol.27, p.vi86-vi86

2016

Volltextzugriff (PDF)

344PFirst report of real-world patient characteristics and treatment patterns from POLARIS: Palbociclib in hormone receptor-positive (HR+) advanced breast cancer: A prospective, multicenter, noninterventional study

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Patient Selection for Anti-Egfviii Therapies in Glioblastoma Multiforme (GBM): Use of Circulating Tumor DNA

Annals of oncology, 2013-03, Vol.24, p.i27-i27

2013

Volltextzugriff (PDF)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer

Breast cancer targets and therapy, 2021-01, Vol.13, p.539-557

2021

Volltextzugriff (PDF)

Abstract PD3-04: Analysis of ERBB2 (HER2) amplification by ctDNA in a phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib in women with metastatic disease with initially diagnosed HER2+ breast cancer: NSABP FB-10

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD3-04-PD3-04

2019

Volltextzugriff (PDF)

Poster session 4. Molecular diagnosis & biomarkers

Annals of oncology, 2013-03, Vol.24 (suppl 1), p.i27-i29

2013

Volltextzugriff (PDF)

718TiP DEKA-1 a dose-finding phase I trial: Observing safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors with progressive disease failing systemic therapy

Annals of oncology, 2023-10, Vol.34, p.S496-S496

2023

Volltextzugriff (PDF)

MicroRNAs 206 and 21 Cooperate To Promote RAS-Extracellular Signal-Regulated Kinase Signaling by Suppressing the Translation of RASA1 and SPRED1

Molecular and cellular biology, 2014-11, Vol.34 (22), p.4143-4164

2014

Volltextzugriff (PDF)

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

Targeted oncology, 2017-06, Vol.12 (3), p.323-332

2017

Volltextzugriff (PDF)

Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer

Molecular cancer therapeutics, 2016-08, Vol.15 (8), p.1809-1822

2016

Volltextzugriff (PDF)

P2.10A.02 Phase 1/1b Trial of MBRC-101, An Anti-EphA5 Monomethyl Auristatin (MMAE) Antibody Drug Conjugate, In Advanced Refractory Solid Tumors

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S243-S244

2024

Volltextzugriff (PDF)

1812TiP IDeate-Lung03: A Phase Ib/II study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first-line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC)

Annals of oncology, 2024-09, Vol.35, p.S1074-S1074

2024

Volltextzugriff (PDF)

678TiP A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations

Annals of oncology, 2024-09, Vol.35, p.S528-S529

2024

Volltextzugriff (PDF)

Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients

Journal of neuro-oncology, 2013-10, Vol.115 (1), p.27-35

2013

Volltextzugriff (PDF)

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

Journal of clinical oncology, 2019-10, Vol.37 (29), p.2601-2609

2019

Volltextzugriff (PDF)

Prognostic factors in breast cancer patients evaluated by PET/CT prior to neoadjuvant chemotherapy

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e12113-e12113

2017

Volltextzugriff (PDF)

Understanding palbociclib practice patterns in a real-world setting

Journal of clinical oncology, 2019-09, Vol.37 (27_suppl), p.200-200

2019

Volltextzugriff (PDF)

Abstract PD1-09: Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic breast cancer previously treated with everolimus

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD1-09-PD1-09

2019

Volltextzugriff (PDF)

NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.1027-1027

2018

Volltextzugriff (PDF)

Prognostic factors in breast cancer patients evaluated by positron-emission tomography/computed tomography before neoadjuvant chemotherapy

World journal of nuclear medicine, 2018-10, Vol.17 (4), p.275-280

2018

Volltextzugriff (PDF)

Optimal management of sentinel lymph node positive biopsy patients in early breast cancer

Annals of translational medicine, 2015-05, Vol.3 (7), p.87-87

2015

Volltextzugriff (PDF)

A Dose Escalation Single Arm Phase Ib Combination Study of BEZ235 with Everolimus in Patients with Advanced Solid Malignancies

Annals of oncology, 2015-03, Vol.26, p.ii16

2015

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

8 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

First report of real-world patient characteristics and treatment patterns from POLARIS: Palbociclib in hormone receptor-positive (HR+) advanced breast cancer: A prospective, multicenter, noninterventional study

Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer

Phase 1b/2 safety and efficacy of TAK-228 (MLN0128), plus exemestane (E) or fulvestrant (F) in postmenopausal women with ER + /HER2- metastatic breast cancer (MBC)

344PFirst report of real-world patient characteristics and treatment patterns from POLARIS: Palbociclib in hormone receptor-positive (HR+) advanced breast cancer: A prospective, multicenter, noninterventional study

Patient Selection for Anti-Egfviii Therapies in Glioblastoma Multiforme (GBM): Use of Circulating Tumor DNA

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer

Abstract PD3-04: Analysis of ERBB2 (HER2) amplification by ctDNA in a phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib in women with metastatic disease with initially diagnosed HER2+ breast cancer: NSABP FB-10

Poster session 4. Molecular diagnosis & biomarkers

718TiP DEKA-1 a dose-finding phase I trial: Observing safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors with progressive disease failing systemic therapy

MicroRNAs 206 and 21 Cooperate To Promote RAS-Extracellular Signal-Regulated Kinase Signaling by Suppressing the Translation of RASA1 and SPRED1

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer

P2.10A.02 Phase 1/1b Trial of MBRC-101, An Anti-EphA5 Monomethyl Auristatin (MMAE) Antibody Drug Conjugate, In Advanced Refractory Solid Tumors

1812TiP IDeate-Lung03: A Phase Ib/II study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first-line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC)

678TiP A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations

Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

Prognostic factors in breast cancer patients evaluated by PET/CT prior to neoadjuvant chemotherapy

Understanding palbociclib practice patterns in a real-world setting

Abstract PD1-09: Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic breast cancer previously treated with everolimus

NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC)

Prognostic factors in breast cancer patients evaluated by positron-emission tomography/computed tomography before neoadjuvant chemotherapy

Optimal management of sentinel lymph node positive biopsy patients in early breast cancer

A Dose Escalation Single Arm Phase Ib Combination Study of BEZ235 with Everolimus in Patients with Advanced Solid Malignancies

Suchergebnisse filtern